In a second EU approval today, Johnson & Johnson got a green light for Akeega (niraparib and abiraterone acetate) for the ...

GSK has signed an eleventh-hour agreement to give Alfasigma rights to its primary biliary cholangitis (PBC) therapy ...

The opening months of 2026 painted a vivid picture of a life sciences sector in rapid motion, stretched between scientific ...

Ipsen said it will now pull Tazverik from the market in all countries where it has rights to the first-in-class, chemotherapy ...

Roche's recent run of positive study results with giredestrant has come to an end with the failure of the persevERA trial in ...

Prasad was first appointed head of the FDA's Center for Biologics Evaluation and Research (CBER) in May 2025 – after his ...

STEM has spent nearly two decades supporting pharma companies with strategic insights. As Adam Boucher explained, the emergence of generative AI has opened new possibilities for analysing field ...

Daiichi Sankyo's European division has signed a partnership with German digital health company GAIA to sell a digital ...

This week's round-up of pharma licensing deals features alliances involving Tenaya Therapeutics, Sino Bio, Antengene, and A2A ...

So, on the strength of that trial, Blackman and Grant paid $1 million (plus $10 million in Day One stock) to Takeda and $2 ...

The UK government is providing nearly £50 million in funding for equipment that it says will help the NHS carry out ...